Modelling the Immune Response to Cancer: An Individual-Based Approach Accounting for the Difference in Movement Between Inactive and Activated T Cells

A growing body of experimental evidence indicates that immune cells move in an unrestricted search pattern if they are in the pre-activated state, whilst they tend to stay within a more restricted area upon activation induced by the presence of tumour antigens. This change in movement is not often considered in the existing mathematical models of the interactions between immune cells and cancer cells. With the aim to fill such a gap in the existing literature, in this work we present a spatially structured individual-based model of tumour–immune competition that takes explicitly into account the difference in movement between inactive and activated immune cells. In our model, a Lévy walk is used to capture the movement of inactive immune cells, whereas Brownian motion is used to describe the movement of antigen-activated immune cells. The effects of activation of immune cells, the proliferation of cancer cells and the immune destruction of cancer cells are also modelled. We illustrate the ability of our model to reproduce qualitatively the spatial trajectories of immune cells observed in experimental data of single-cell tracking. Computational simulations of our model further clarify the conditions for the onset of a successful immune action against cancer cells and may suggest possible targets to improve the efficacy of cancer immunotherapy. Overall, our theoretical work highlights the importance of taking into account spatial interactions when modelling the immune response to cancer cells.

[1]  A. Molinaro,et al.  A preliminary mathematical model of skin dendritic cell trafficking and induction of T cell immunity , 2009 .

[2]  Fenghua Wang,et al.  In Silico Synergism and Antagonism of an Anti-tumour System Intervened by Coupling Immunotherapy and Chemotherapy: A Mathematical Modelling Approach , 2011, Bulletin of Mathematical Biology.

[3]  Rebecca H. Chisholm,et al.  Mathematical model reveals how regulating the three phases of T‐cell response could counteract immune evasion , 2015, Immunology.

[4]  R. Yasuda,et al.  Combination of monocyte-derived dendritic cells and activated T cells which express CD40 ligand: a new approach to cancer immunotherapy , 2003, Cancer Immunology, Immunotherapy.

[5]  M. Donia,et al.  Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen , 2016, Clinical Cancer Research.

[6]  E. Mardis,et al.  A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells , 2015, Science.

[7]  Frederic Bartumeus,et al.  Stochastic Optimal Foraging: Tuning Intensive and Extensive Dynamics in Random Searches , 2014, PloS one.

[8]  Hiroaki Ikeda,et al.  T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells. , 2016, International immunology.

[9]  Matthew J. Frigault,et al.  Chimeric antigen receptor-modified T cells strike back. , 2016, International immunology.

[10]  Alberto d'Onofrio,et al.  Simple biophysical model of tumor evasion from immune system control. , 2011, Physical review. E, Statistical, nonlinear, and soft matter physics.

[11]  F. Garrido,et al.  “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy , 2010, International journal of cancer.

[12]  Z. Eshhar,et al.  Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy. , 2016, Annual review of pharmacology and toxicology.

[13]  W. Oyen,et al.  Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. , 2013, Cancer research.

[14]  Y. Bae,et al.  DC immunotherapy is highly effective for the inhibition of tumor metastasis or recurrence, although it is not efficient for the eradication of established solid tumors , 2007, Cancer Immunology, Immunotherapy.

[15]  Peter Friedl,et al.  Amoeboid shape change and contact guidance: T-lymphocyte crawling through fibrillar collagen is independent of matrix remodeling by MMPs and other proteases. , 2003, Blood.

[16]  Badal Joshi,et al.  On immunotherapies and cancer vaccination protocols: a mathematical modelling approach. , 2009, Journal of theoretical biology.

[17]  Mikala Egeblad,et al.  Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. , 2012, Cancer cell.

[18]  Frederic Bartumeus,et al.  T cell migration, search strategies and mechanisms , 2016, Nature Reviews Immunology.

[19]  Carlo Cattani,et al.  Metamodeling the learning-hiding competition between tumours and the immune system: A kinematic approach , 2010, Math. Comput. Model..

[20]  Sebastian Amigorena,et al.  In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor , 2007, The Journal of experimental medicine.

[21]  G. D. Knott,et al.  Modeling tumor regrowth and immunotherapy , 2001 .

[22]  S. Spranger Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. , 2016, International immunology.

[23]  L. Zitvogel,et al.  Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  D. Stauffer,et al.  A discrete model for immune surveillance, tumor immunity and cancer. , 1991, Journal of theoretical biology.

[25]  Philip Hahnfeldt,et al.  Mathematical models of immune-induced cancer dormancy and the emergence of immune evasion , 2013, Interface Focus.

[26]  E. Jaffee,et al.  Targeting neoantigens to augment antitumour immunity , 2017, Nature Reviews Cancer.

[27]  G. Prendergast,et al.  How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances. , 2016, The oncologist.

[28]  Ramon Arens,et al.  In Vivo Killing Capacity of Cytotoxic T Cells Is Limited and Involves Dynamic Interactions and T Cell Cooperativity , 2016, Immunity.

[29]  Weiyang Jin,et al.  Cytotoxic T Cells Use Mechanical Force to Potentiate Target Cell Killing , 2016, Cell.

[30]  Arancha Casal,et al.  Agent-based modeling of the context dependency in T cell recognition. , 2005, Journal of theoretical biology.

[31]  Gil Ariel,et al.  Swarming bacteria migrate by Lévy Walk , 2015, Nature Communications.

[32]  P. Agostinis,et al.  Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape. , 2017, Trends in immunology.

[33]  Azuma Ohuchi,et al.  A Mathematical Analysis of the Interactions between Immunogenic Tumor Cells and Cytotoxic T Lymphocytes , 2001, Microbiology and immunology.

[34]  Grant Lythe,et al.  How many dendritic cells are required to initiate a T-cell response? , 2012, Blood.

[35]  L. Butterfield Dendritic Cells in Cancer Immunotherapy Clinical Trials: Are We Making Progress? , 2013, Front. Immunol..

[36]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[37]  D. G. Mallet,et al.  Spatial tumor-immune modeling , 2006 .

[38]  Marcello Edoardo Delitala,et al.  Recognition and learning in a mathematical model for immune response against cancer , 2013 .

[39]  Nicola Bellomo,et al.  From the mathematical kinetic, and stochastic game theory to modelling mutations, onset, progression and immune competition of cancer cells ✩ , 2008 .

[40]  F. Detcheverry Generalized run-and-turn motions: From bacteria to Lévy walks. , 2017, Physical review. E.

[41]  A. Perelson,et al.  Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. , 1994, Bulletin of mathematical biology.

[42]  Kerry A Landman,et al.  A dynamical model of tumour immunotherapy. , 2014, Mathematical biosciences.

[43]  B. Neyns,et al.  Therapeutic Vaccination With an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Advanced Melanoma , 2011, Journal of immunotherapy.

[44]  M. Chaplain,et al.  Evasion of tumours from the control of the immune system: consequences of brief encounters , 2012, Biology Direct.

[45]  Wolfgang Weninger,et al.  Leukocyte migration in the interstitial space of non-lymphoid organs , 2014, Nature Reviews Immunology.

[46]  D. Cockcroft,et al.  Induction of type 2 T helper cell allergen tolerance by IL-10-differentiated regulatory dendritic cells. , 2010, American journal of respiratory cell and molecular biology.

[47]  P. Hersey,et al.  How melanoma cells evade trail-induced apoptosis , 2001, Nature Reviews Cancer.

[48]  P. Mainwaring,et al.  A Phase I Clinical Trial of CD1c (BDCA-1)+ Dendritic Cells Pulsed With HLA-A*0201 Peptides for Immunotherapy of Metastatic Hormone Refractory Prostate Cancer , 2015, Journal of immunotherapy.

[49]  Marina E. Wosniack,et al.  The evolutionary origins of Lévy walk foraging , 2017, PLoS Comput. Biol..

[50]  Salvatore Musumeci,et al.  Modeling immune system control of atherogenesis , 2008, Bioinform..

[51]  B. Neyns,et al.  Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  A. Tres,et al.  Dendritic cell uptake of iron‐based magnetic nanoparticles , 2008, Cell biology international.

[53]  Mark A J Chaplain,et al.  Mathematical modelling of the spatio-temporal response of cytotoxic T-lymphocytes to a solid tumour. , 2004, Mathematical medicine and biology : a journal of the IMA.

[54]  J. E. Brewer,et al.  T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells , 2015, Clinical and experimental immunology.

[55]  Y. Bae,et al.  Dendritic cell-based therapeutic cancer vaccines: past, present and future , 2014, Clinical and experimental vaccine research.

[56]  Ferdinando Chiacchio,et al.  Mathematical modeling of the immune system recognition to mammary carcinoma antigen , 2012, BMC Bioinformatics.

[57]  C. Figdor,et al.  Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells , 2015, Clinical Cancer Research.

[58]  G. Coukos,et al.  Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes , 2011, Journal of Translational Medicine.

[59]  P. Cattiaux,et al.  A Biased Competition Theory of Cytotoxic T Lymphocyte Interaction with Tumor Nodules , 2015, PloS one.

[60]  Andrea J. Liu,et al.  Generalized Lévy walks and the role of chemokines in migration of effector CD8+ T cells , 2012, Nature.

[61]  J. Modiano,et al.  Fas ligand based immunotherapy: A potent and effective neoadjuvant with checkpoint inhibitor properties, or a systemically toxic promoter of tumor growth? , 2016, Discovery medicine.

[62]  Melanie E. Moses,et al.  Persistence and Adaptation in Immunity: T Cells Balance the Extent and Thoroughness of Search , 2016, PLoS Comput. Biol..

[63]  S. Abrams,et al.  How tumours escape mass destruction , 2008, Oncogene.

[64]  Svetlana Bunimovich-Mendrazitsky,et al.  Mathematical Model of Pulsed Immunotherapy for Superficial Bladder Cancer , 2008, Bulletin of mathematical biology.

[65]  Mikhail Kolev,et al.  Mathematical modeling of the competition between acquired immunity and cancer , 2003 .